"Our capacity to run large clinical trials has increased significantly with this five-fold increase in laboratory space. This will facilitate large scale manual and automated robotic testing. We will now have the ability to work on several large trials at the same time, namely: the frontline screening colorectal cancer tests and lung, prostate and pancreatic cancer," said Dr. Marielle Herzog, R&D director of Volition.
"We are delighted to have moved into our new R&D facility as we have outgrown our previous premises. This exciting upgrade allows us to accelerate our clinical trials and expedite the commercialization of our products," said Dr. Gaetan Michel, chief executive officer of Belgian Volition.